News
LGNXZ
0.0020
NaN%
--
Ligand outlines 23% CAGR royalty growth outlook through 2030 as royalty portfolio accelerates
Seeking Alpha · 02/26 22:48
Stifel Maintains Ligand Pharmaceuticals Incorporated - Equity Right (LGNXZ) Buy Recommendation
NASDAQ · 12/11/2025 04:15
RBC Capital Maintains Ligand Pharmaceuticals Incorporated - Equity Right (LGNXZ) Outperform Recommendation
NASDAQ · 12/11/2025 04:15
Citigroup Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right (LGNXZ) with Buy Recommendation
NASDAQ · 12/10/2025 01:14
Weekly Report: what happened at LGNXZ last week (0908-0912)?
Weekly Report · 09/15/2025 11:49
Weekly Report: what happened at LGNXZ last week (0901-0905)?
Weekly Report · 09/08/2025 11:51
Weekly Report: what happened at LGNXZ last week (0825-0829)?
Weekly Report · 09/01/2025 11:45
Weekly Report: what happened at LGNXZ last week (0818-0822)?
Weekly Report · 08/25/2025 11:59
More
Webull provides a variety of real-time LGNXZ stock news. You can receive the latest news about Ligand Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LGNXZ
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.